This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Pfizer is committed to supporting your patients throughout their treatment journey. With Pfizer Oncology Together, patients prescribed NYVEPRIA® (pegfilgrastim-apgf) get personalized support, including help identifying financial assistance options and connections to resources that may help with some of their day-to-day challenges.
Help your patients and their caregivers stay connected and get organized by telling them about LivingWith®, a free app developed by Pfizer Oncology, designed to help manage life with cancer.
Visit ThisIsLivingWithCancer.com to learn more. Available in English and Spanish. Download LivingWith for free.
The LivingWith app is available to anyone living with cancer and their loved ones, and is not specific to NYVEPRIA.
App Store is a service mark of Apple Inc., registered in the US and other countries. Google Play and the Google Play logo are trademarks of Google LLC.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
Contraindications
NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use
NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.